{"transactions":[{"id":890592,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T16:16:45.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":35000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-061396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312526061396/ownership.xml","form_type":"4"}},{"id":981437,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-03T16:16:39.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":false,"shares":4225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":15775,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":4225},"source":{"system":"sec-edgar","filing":"0001193125-25-306729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312525306729/ownership.xml","form_type":"4"}},{"id":981436,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T16:16:39.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":true,"shares":4225,"price":0.511,"value":2158.975,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 6,870 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":26095,"source":{"system":"sec-edgar","filing":"0001193125-25-306729","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312525306729/ownership.xml","form_type":"4"}},{"id":1124792,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T16:00:39.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":8550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 8,550 shares of common stock."}],"balance_after":13110,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":8550},"source":{"system":"sec-edgar","filing":"0000950170-25-080889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025080889/ownership.xml","form_type":"4"}},{"id":1209560,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T16:00:06.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":4560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":4560,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":4560},"source":{"system":"sec-edgar","filing":"0000950170-25-037882","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025037882/ownership.xml","form_type":"4"}},{"id":1255647,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:00:03.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 41,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":41000,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000950170-25-024109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025024109/ownership.xml","form_type":"4"}},{"id":1328528,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-17T16:30:03.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":20000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-137255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017024137255/ownership.xml","form_type":"4"}},{"id":1328527,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-17T16:30:03.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.511,"value":7665.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,935 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":19935,"source":{"system":"sec-edgar","filing":"0000950170-24-137255","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017024137255/ownership.xml","form_type":"4"}},{"id":1638171,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T16:44:29.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 15, 2024. The 28,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028."}],"balance_after":28500,"derivative":{"exercise_price":2.38,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000950170-24-016469","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017024016469/ownership.xml","form_type":"4"}},{"id":2010958,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T17:34:26.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2023. The 40,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027."}],"balance_after":40000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-010202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000120919123010202/doc4.xml","form_type":"4"}},{"id":2394410,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-15T16:00:36.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-22-009739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000120919122009739/doc4.xml","form_type":"4"}},{"id":2748577,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-15T19:04:18.000Z","date":"2021-04-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on April 13, 2021. The 25,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on April 12, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter, through April 12, 2025."}],"balance_after":25000,"derivative":{"exercise_price":2.53,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-016010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000089924321016010/doc4.xml","form_type":"4"}}]}